AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition

13 12 2021 10:30:00 提供 Nasdaq GlobeNewswire

Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition

13 12 2021 07:00:01 提供 Nasdaq GlobeNewswire

Agios Appoints Richa Poddar as Chief Commercial Officer

15 11 2021 16:01:00 提供 Nasdaq GlobeNewswire

Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition

04 11 2021 09:00:01 提供 Nasdaq GlobeNewswire

Agios Reports Business Highlights and Third Quarter 2021 Financial Results

03 11 2021 07:10:58 提供 Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021

21 10 2021 16:01:00 提供 Nasdaq GlobeNewswire

Agios To Present at September Investor Conferences

30 8 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

17 8 2021 16:01:00 提供 Nasdaq GlobeNewswire

Agios Reports Business Highlights and Second Quarter 2021 Financial Results

29 7 2021 07:00:03 提供 Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021

15 7 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

28 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency

22 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

21 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress

11 6 2021 03:00:00 提供 Nasdaq GlobeNewswire

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

11 6 2021 03:00:00 提供 Nasdaq GlobeNewswire

Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress

12 5 2021 10:00:00 提供 Nasdaq GlobeNewswire

Agios Reports Business Highlights and First Quarter 2021 Financial Results

29 4 2021 07:00:01 提供 Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021

15 4 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Announces Closing of Oncology Business Sale to Servier

01 4 2021 07:00:00 提供 Nasdaq GlobeNewswire

Agios Shareholders Approve Sale of Oncology Business to Servier

25 3 2021 16:01:00 提供 Nasdaq GlobeNewswire